Effect of Weikangning on gastric cancer cell growth and expression of vascular endothelial growth factor and its receptors KDR and Flt-1

Table 1 Primers for PCR.

	Positive	Negative
VEGF	5'ATGCTTTCTCCGCTCTG3'	5'TGCTGCTCTACCTCCAC3'
Flt-1	5'AAGTGGCCAGAGGCATGGAGTT3'	5'ATGTAGTCTTTACCATCCTGTTG3'
KDR	5'AGGGCCTCTCATGGTGATTGT3'	5'GCCAGCAGTCCAGCATGGTCTG3'
β-actin	5'TAYYGGCAACGAGCGGTTC3'	5'TTAGGAGTGGGGGTGGCTT3'

Table 2 Proportion of cells in different phases of cell cycle of different groups.

Groups	Proportion of cells (%)
	G0-G1 phase	G2-S phase	S phase
High dose	65.40±0.41ab	11.62±0.62ab	22.99±0.69ab
Medium dose	56.92±0.62ab	17.08±0.80ab	26.00±0.71ab
Low dose	55.89±0.69ab	19.37±0.57ab	24.74±0.64ab
Serum	42.25±0.25	22.51±0.58	35.34±0.56
Control	41.35±0.55	23.65±0.56	35.00±0.60

^aP<0.05 between high, medium, and low dose groups,

^bP<0.01 vs control group.

Table 3 Effect of WKN on the mRNAs of VEGF and its receptors KDR and Flt-1.

Groups		High dose	Medium dose	Low dose	Serum	Control
VEGF	AREA	120b	134ab	192ab	261	297
	OPTDM	0.072b	0.107ab	0.140ab	0.152	0.174
	APTDI	8.588b	14.373ab	25.856ab	39.555	50.85
KDR	AREA	79b	178ab	239ab	272	408
	OPTDM	0.237b	0.112ab	0.150ab	0.162	0.282
	APTDI	18.752b	19.883ab	35.764	44.183	115.242
	AREA	111b	197ab	247ab	271	306
Flt-1	OPTDM	0.061b	0.275ab	0.340ab	0.368	0.407
	APTDI	6.805b	54.256ab	84.040ab	99.600	124.531

^aP<0.05 vs high dose group,

^bP<0.01 vs control group.